Thrombolytic agents
Thrombolytic agents ( 5 Questions)
A nurse is reviewing the contraindications for thrombolytic therapy for a client with a peripheral arterial occlusion. Which of the following conditions would make the client ineligible for this therapy? (Select all that apply.)
Choice A is correct because tenecteplase is administered as a single intravenous bolus injection over 5 seconds. This is an advantage over other thrombolytic agents, such as alteplase, that require infusion over 90 minutes.
Choice B is correct because tenecteplase helps dissolve the clot that is blocking the coronary artery and causing the acute myocardial infarction. By restoring blood flow to the ischemic myocardium, tenecteplase can reduce infarct size, preserve left ventricular function, and improve survival.
Choice C is correct because tenecteplase can cause bleeding as a major adverse effect. This is due to its nonspecific action on fibrinogen and plasminogen, which leads to systemic fibrinolysis and depletion of clotting factors. Patients on tenecteplase should be monitored for signs of bleeding, such as hematuria, hematemesis, melena, petechiae, ecchymoses, and prolonged bleeding from puncture sites.
This statement indicates a need for further teaching because tenecteplase is a thrombolytic agent, not an anticoagulant. Thrombolytic agents work by dissolving existing clots, but they do not prevent new clots from forming. Anticoagulants, such as heparin or warfarin, are used to prevent clot formation by inhibiting the coagulation cascade.
No explanation
This medication will prevent any future clots from forming in my blood vessels.
This statement indicates a need for further teaching because tenecteplase is a thrombolytic agent, not an anticoagulant. Thrombolytic agents work by dissolving existing clots, but they do not prevent new clots from forming. Anticoagulants, such as heparin or warfarin, are used to prevent clot formation by inhibiting the coagulation cascade.
Choice A is correct because tenecteplase is administered as a single intravenous bolus injection over 5 seconds. This is an advantage over other thrombolytic agents, such as alteplase, that require infusion over 90 minutes.
Choice B is correct because tenecteplase helps dissolve the clot that is blocking the coronary artery and causing the acute myocardial infarction. By restoring blood flow to the ischemic myocardium, tenecteplase can reduce infarct size, preserve left ventricular function, and improve survival.
Choice C is correct because tenecteplase can cause bleeding as a major adverse effect. This is due to its nonspecific action on fibrinogen and plasminogen, which leads to systemic fibrinolysis and depletion of clotting factors. Patients on tenecteplase should be monitored for signs of bleeding, such as hematuria, hematemesis, melena, petechiae, ecchymoses, and prolonged bleeding from puncture sites.